Francesco Gelsomino. Overcoming primary resistance to PD-1 inhibitor with anti-PD-L1 agent in squamous NSCLC: a case report.2019
Francesco Gelsomino. Overcoming primary resistance to PD-1 inhibitor with anti-PD-L1 agent in squamous NSCLC: a case report.2019 来自:找药宝典>《待分类》
FrancescoGelsomino.OvercomingprimaryresistancetoPD-1inhibitorwithanti-PD-L1agentinsquamousNSCLC:acasereport.2019 版权声明 本文版权归找药宝典所有
近日,Clinical Lung Cancer发表了一篇非常有趣的治疗个案。患者在PD1耐药后尝试PDL1竟然取得了很好的效果。这种治疗方案并非凭空而来,其实还有一定的细节讲究,一起来看看。 病·例·分·享 基本情况:局晚期TP53突变、PDL1阳性老年患者 患者,女,79岁,吸烟者,...
C. Franke, N. Basara, J. Atz, R. Kaiser, Nintedanib plus docetaxel after progression on immune checkpoint inhibitor therapy: insights from VARGADO, a prospective study in patients with lung adenocarcinoma, Future Oncol. 15 (23) (2019) 2699–2706, https:///10.2217/fon-2019-0262. ...
[26]Hunter, Katerina Ancevski, Mark A. Socinski, and Liza C. Villaruz. PD-L1 testing in guiding patient selection for PD-1/PD-L1 inhibitor therapy in lung cancer. Molecular diagnosis & therapy 22.1 (2018): 1-10. [27]Hirsch, Fred R., et al. PD-L1 immunohistochemistry assays for lu...
1. Kohei Fujita et al. Retreatment With Anti-PD-L1 Antibody in Advanced Non-small Cell Lung Cancer Previously Treated With Anti-PD-1 Antibodies.2019 2. Maiko Niki et al. Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer.2018 ...
2. Hironori Ashinuma et al. A Case of Long-Term Survival after Checkpoint Inhibitor Pneumonitis in a Patient with Squamous Cell Lung Cancer.2019 声明:本资料中涉及的信息仅供参考,请遵从医生或其他医疗卫生专业人士的意见或指导。 本文版权归...
9 H i r s c h F R , Mc e l h i n n y A , S t a n f o r t h D, e t a l . P D - L 1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol, 2017, 12(2): 208-222. doi: 10.1016...
进 2 一步加入4μl 5x PrimeScript II Buffer+0.5μl RNase Inhibitor+1.0μl PrimeScript II RTase+4.5μl RNase‑free ddH O(共20μl体系),配好后混匀,使用PCR仪运行40℃50min 2 后,转70℃运行10min,完成cDNA合成。 [0069] cDNA进一步在3’端加Poly G,反应体系...